{"org_id": "T000026576", "org_name_cn": "深圳市海普瑞药业集团股份有限公司", "org_short_name_cn": "海普瑞", "org_name_en": "Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.", "org_short_name_en": "HEPALINK", "main_operation_business": "肝素产业链、生物大分子CDMO和创新药物的投资、开发和商业化。", "operating_scope": "　　开发、生产经营原料药（肝素钠），从事货物及技术进出口（不含分销及国家专营、专控、专卖商品）。", "district_encode": "440305", "org_cn_introduction": "深圳市海普瑞药业集团股份有限公司是一家从事肝素产业链、生物大分子CDMO和创新药物的投资、开发和商业化的企业。主要产品和服务包括依诺肝素钠制剂、肝素钠和依诺肝素钠原料药，以及大分子药物CDMO服务。本公司是全球产销规模最大、也是我国唯一同时取得美国FDA认证和欧盟CEP认证的肝素钠原料药生产企业。公司作为欧盟依诺肝素生物类似物市场的先驱者，公司已在知名医院以及医学专家中树立了良好的品牌声誉。", "legal_representative": "李锂", "general_manager": "单宇", "secretary": "谈煊", "established_date": 893088000000, "reg_asset": 1467296204.0000002, "staff_num": 1957, "telephone": "86-755-26980311", "postcode": "518057", "fax": "86-755-86142889", "email": "stock@hepalink.com", "org_website": "www.hepalink.com", "reg_address_cn": "广东省深圳市南山区松坪山郎山路21号", "reg_address_en": "", "office_address_cn": "广东省深圳市南山区松坪山郎山路21号", "office_address_en": "", "currency_encode": "019001", "currency": "CNY", "listed_date": 1273075200000, "provincial_name": "广东省", "actual_controller": "李锂 (35.02%)，李坦 (27.89%)", "classi_name": "民营企业", "pre_name_cn": "深圳市海普瑞药业股份有限公司", "chairman": "李锂", "executives_nums": 11, "actual_issue_vol": 40100000.0, "issue_price": 148.0, "actual_rc_net_amt": 5716804191.000001, "pe_after_issuing": 73.27, "online_success_rate_of_issue": 1.24750499, "affiliate_industry": {"ind_code": "BK0040", "ind_name": "化学制药"}}